Seismic Therapeutic Announces Presentation of Preclinical Data for Immunoglobin Sculpting Enzyme and Dual-Cell Bidirectional Antibody Programs at IMMUNOLOGY 2023

Demonstrates the application of the IMPACT platform to design novel protein therapeutics

Seven poster presentations and two oral presentations support discovery, optimization, and characterization of Ig sculpting enzymes and dual-cell bidirectional antibody programs to control dysregulated adaptive immunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced seven poster presentations and two oral presentations supporting the company’s emerging pipeline of immunoglobin (Ig) sculpting enzymes and dual-cell bidirectional (DcB) antibody programs at IMMUNOLOGY 2023, the annual meeting of the American Association of Immunologists (AAI) taking place on May 11-15 in Washington, D.C. Seismic is designing novel biologics derived from the company’s proprietary IMPACT platform to address unmet medical needs for diseases involving humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system.

Seismic’s Ig sculpting enzymes address dysregulated humoral immunity by reducing both Ig levels and antibody effector functions, which contribute to the pathogenesis of a wide range of autoimmune diseases, such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia. Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation. The presentations demonstrate the application of the IMPACT platform to reduce immunogenicity while retaining the function of novel Ig sculpting enzymes for the acute and chronic treatment of autoantibody-driven diseases.

Seismic’s DcB antibody approach targets dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells (APCs), such as B cells to restore homeostasis. Activating these pathways may control multiple diseases, such as multiple sclerosis, lupus and rheumatoid arthritis. The presentations demonstrate the application of IMPACT platform to identify and optimize novel antibody molecules that simultaneously engage multiple inhibitory pathways in more than one immune cell type, thereby targeting and regulating both sides of the immune synapse.

“We are excited by the meaningful progress of our growing pipeline of novel biologics to treat humoral and cell-mediated autoimmune diseases,” said John Sundy, MD, PhD, Chief Medical Officer and Head of R&D of Seismic Therapeutic. “Our lead Ig sculpting program, a pan-IgG protease, is suitable for the treatment of acute and chronic autoantibody mediated diseases. We are also applying our insights to design additional Ig sculpting enzymes that are selective for IgG subclasses and other Ig isotypes. We are advancing our lead DcB antibody program which agonizes an inhibitory checkpoint receptor on T cells and selectively engages the inhibitory Fc receptor FcγRIIb on B cells/APCs to restore homeostasis in cell-mediated autoimmune diseases.”

Details of the poster presentations at IMMUNOLOGY 2023 are as follows:

Ig Sculpting Enzyme Programs

Identifying next generation Ig selective cleaving enzymes for treatment of autoimmune diseases using IMPACT platform
Sunday, May 14^th 2:30-3:45 p.m.
Poster Board Number: P900
Author: Purvi Mande, PhD

The promise of machine learning: using Seismic’s IMPACT platform to design a class of IgG cleaving enzymes with drug like properties and reduced immunogenicity for the chronic treatment of autoimmune diseases
Friday, May 12^th 2:30-3:45 p.m.
Poster Board Number: P969
Author: Alex Pellerin, PhD

In vitro assay development to assess successful removal of T and B cell epitopes through Seismic’s IMPACT platform
Friday, May 12^th 2:30-3:45 p.m.
Poster Board Number: P972
Author: Andita Newton, B.S.

In vivo PK/PD assessment of invisibilized IgG cleaving protease for chronic treatment of autoimmune diseases
Sunday, May 14^th 2:30-3:45 p.m.
Poster Board Number: P764
Author: Liliana Sanmarco, PhD

High-throughput Western Blot for in vitro and in vivo assessment of human Ig specific cleaving enzymes
Sunday, May 14^th 2:30-3:45 p.m.
Poster Board Number: P767
Author: Nam Le, B.S.

DcB Antibody Programs

IMPACTing autoimmunity through dual targeting of antigen presenting cells and T cells via inhibitory receptor agonism
Saturday, May 13^th 2:30-3:45 p.m.
Poster Board Number: P428
Author: Stephanie Grebinoski, PhD

Identification and characterization of selective FcγRIIb binders and their potential of IMPACTing immune-mediated diseases
Sunday, May 14^th 2:30-3:45 p.m.
Poster Board Number: P769
Author: Stephen Lutz, B.S.

Details of the oral presentations at IMMUNOLOGY 2023 are as follows:

• Jo Viney, PhD, Co-Founder, President and CEO of Seismic, will present on the Ig sculpting enzyme program in a session titled “Human Immunological Diseases and Pathologies: Current Standard of Care, Mechanisms of Action, and Unmet Needs,” sponsored by the AAI Clinical Immunology Committee, on Friday, May 12 at 10:15 a.m. in Room 202B.
• Stephanie Grebinoski, PhD, Scientist in Immunology at Seismic, will present on the dual-cell bidirectional antibody program in the session “Emerging Approaches in Oncology and Autoimmunity,” chaired by Daniela Cipolletta, PhD, Director of Immunology at Seismic, on Friday, May 12 at 12:30 p.m. in Room 206.

About the IMPACT Platform

The IMPACT platform “parallelizes” interdisciplinary components of drug discovery to generate drug molecules on an unprecedented scale that are engineered to be better therapeutics to treat autoimmune diseases. Comprehensive integration of machine learning with protein engineering, structural biology and translational immunology enables the accelerated design and analysis of vast numbers of proteins and protein modifications. This parallelized process bypasses the trial and error methods of conventional biologics development, enabling simultaneous optimization for biologic function, reduced immunogenicity and developability, resulting in the creation of novel biologics with superior properties.

About Seismic Therapeutic

Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow up on Twitter @Seismic_Tx and on LinkedIn.

Media
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com